Treatment with TAK-242 reversed cardiac hypertrophy in rats, as indicated by reduced HW/BW ratio, decreased cross-sectional area of cardiomyocytes, and downregulation of hypertrophy-related genes, such as ANP, BNP, and β-MHC. This evidence concerns the gene NPPA and cardiac hypertrophy.